Skip to main content

Warning notification:Warning

Unfortunately, you are using an outdated browser. Please, upgrade your browser to improve your experience with HSE. The list of supported browsers:

  1. Chrome
  2. Edge
  3. FireFox
  4. Opera
  5. Safari

Tumour Agnostic Therapy SACT Regimens

NTRK Gene Fusion Testing Guidance (PDF, 922 KB, 11 pages)

NTRK Gene Fusion Positive Solid Tumours

Entrectinib Monotherapy – Adult

Regimen

00702b

For the treatment of adult patient with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,

  • who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
  • who have not received a prior NTRK inhibitor

who have no satisfactory treatment options

Larotrectinib Monotherapy - Adult

Regimen

00758a

For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,

  • who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
  • who have no satisfactory treatment options
Larotrectinib Monotherapy - Paediatric

Regimen

00760a

For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,

  • who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
  • who have no satisfactory treatment options